Carcinoembryonic Antigen Market is Expected to Grow at a CAGR of 15.2% by 2030

Pune, India, Sept, 2022 /MRFR Press Release/- Market Research Future publishes a half cooked research report on the Global Carcinoembryogenic Antigen Market.

Market Highlights

The Carcinoembryonic Antigen Market is projected to reach USD 2,934.5 Million by 2030 at 15.2% CAGR during the forecast period 2022-2030.

Carcinoembryogenic antigen (CEA) is a group of glycoproteins which are produced during the fetal developmental stages by gastrointestinal tissues. CEA is responsible for cell adhesion. Healthy adults do not have CEA concentrations. However, smoking and certain medical conditions such as colorectal cancer, breast cancer etc. can mark the presence of CEA in the body. Thus, CEA based diagnostic assays are used for the detection of such cancers and to check the treatment efficiency during the therapeutic period by a physician.

In 2017, studies of the NCBI suggested that the global burden of colorectal cancer will increase by 60%, leading to 2.2 million new cancer cases and 1.1 million deaths by 2030. This will increase the colorectal cancer diagnostic demands, thereby propelling the market growth.

Increasing prevalence of cancer, rising healthcare expenditures, and developing diagnostic technologies will boost the global market during the forecast period. However, risk of infection and hematoma, lack of awareness and medical services in the developing countries will restrain the market growth during the assessment period.

Market Players

Some of key players profiled in the report are Lee BioSolutions, F. Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated., Correlogic Systems, Inc, Genway Biotech, Inc., Abbott., RayBiotech, Inc., Abcam plc., Biocare Medical, LLC, and Biocare Medical, LLC.

Regional Analysis

The Americas account for the largest share in the carcinoembryogenic antigen market. The Americas mainly include countries like the U.S. and Canada. Increasing prevalence of cancer and high healthcare expenditures within the region will boost the market growth over the assessment period.

Europe is the second highest revenue generating region in the global carcinoembryogenic antigen market. Increasing prevalence of cancer, fast adoption of new technologies and presence of developed countries like Germany and U.K within the region will boost the market growth during the forecasted period.

On account of the developing medical infrastructure, rising healthcare expenditure, and increasing government initiatives, Asia Pacific region is expected to grow the fastest.

The Middle East & Africa is expected to grow slower than the global average. The Middle Eastern countries, for instance, UAE and Saudi Arabia dominates the market due to high income and the government support to improve public health. 

Taste the market data and market information presented through more than 50 market data tables and figures spread over 80 pages of the project report. Avail the in-depth table of content (TOC) & market synopsis on “Global Carcinoembryogenic Antigen Market” Research Report – Forecast till 2030.

Explore In-depth Details: Carcinoembryonic Antigen Market Research Report

Segmentation

The global carcinoembryonic antigen market has been segmented on the basis of application, sampling, and end user.

Based on application, the market has been segmented into colorectal, pancreatic, breast, lung cancer, and others.  

Based on sampling, the market has been segmented into antecubital, peritoneal, pleural, serebrospinal, and others.

Based on the end users, the market has been segmented into hospitals, diagnostic centers, research centers, and others.